Metabolism and Protective Properties of HDL

Size: px
Start display at page:

Download "Metabolism and Protective Properties of HDL"

Transcription

1 Metabolism and Protective Properties of HDL A riddle wrapped in a mystery inside an enigma Jacques Genest MD Cardiovascular Research Laboratories McGill University Health Center

2 Disclosure J. Genest MD 2013 Advisory Board, Speaker s Bureau, Consultant, Grants, Clinical Trials Merck * Pfizer Novartis AMGEN * Roche * AstraZeneca Sanofi/Regeneron * Lilly Valeant Genzyme * Aegerion Stock ownership: none; Off label use: none * Scientific Advisory Relevant disclosure: JUPITER, IMPROVE-IT, CANTOS, CAPREE steering Committees; REVEAL, ACCELERATE, AMG145, Lilly Clinical Trials.

3 The Controversy A low level of HDL-C is a major independent risk factor for atherosclerotic cardiovascular disease. However, in randomized, controlled trials, high-dose niacin or inhibitors of cholesteryl ester transfer protein did not improve CV outcomes despite significantly increasing the HDL-C level. Furthermore, genetic variants associated with HDL-C levels are often not associated with CVD. These observations suggest that HDL cholesterol may not be causally associated with CVD N Engl J Med 2014;371:

4 HDL Metabolism Complexity of HDL HDL Biogenesis HDL Metabolism

5 HDL Metabolism: The Simplified View Circ Res. 2014;114:

6 Human Plasma Lipidome (Quenhenburger N Engl J Med 2011;365: )

7 Human Plasma Lipidome

8 Apolipoprotein AI

9 NH2- Adenosine Triphosphate Binding Cassette Transporter A1 (ABCA1) Full-transporter Phospholipid and (cholesterol) efflux to apoa-i Early HDL maturation LxR/RxR apoa-i - COOH cholesterol & phospholipid ATP ADP+P i ATP ADP+P i

10 HDL Biogenesis Model Iatan I et al. JLR 2011

11 HDL Biogenesis

12 Nascent HDL Particles Sorci-Thomas JLR 2012

13 CE C HDL Biogenesis

14 Two-D PAGGE Analysis of HDL O pre - b a [nm] pre - b 1 - LpA - I a - LpA - I Apo AI-containing lipoproteins Hafiane A. CLC 2013 R17; P18

15 Lipoprotein Metabolism Chylomicron LPL FFA Chylo Remnant HL Liver Exogenous Pathway Intestine ApoA-I, A-II ApoC-I, C-II, C-III Phospholipids Free cholesterol Free Cholesterol HL Peripheral Cells Steroidogenic Cells Liver Nascent HDL LCAT HDL3 HDL2 LDL ApoA-I, A-II ApoC-I, C-II, C-III Phospholipids Free cholesterol Tg CETP PLTP Endogenous Pathway LPL CE 3 Liver HL VLDL IDL FFA Feces

16 Genes involved in HDL regulation HDL-C factors: Environmental Genetic: heritability 50% Known genes: º Mutations in several genes have identified (ApoAI, ABCA1, LCAT ) Novel genes: PCSK5, WWOX 16 Kathiresan S, Cupples L et al. Nat Genet (2009) 41(1): 56-65

17 HDL Functions Cellular Cholesterol Efflux Anti-oxidant Anti-inflammatory Vascular Endothelial function Anti-thrombotic

18 Figure 1 Pleiotropic biological functions of apolipoprotein A-I Shah, P. K. (2011) Targeting endogenous apo A-I a new approach for raising HDL Nat. Rev. Cardiol. doi: /nrcardio

19 ABCA1 Mediated Cellular Cholesterol Efflux LxR/RxR

20 HDL Cholesterol efflux: Biomarker of CVD N Engl J Med 2014;371:

21 CVD, HDL-C and Efflux Capacity N Engl J Med 2014;371:

22 Cholesterol Efflux and CVD Khera AV. N Engl J Med 2011;364:127-35

23 Cholesterol Efflux and CVD Arterioscler Thromb Vasc Biol. 2013;33:

24 hscrp (mg/l) HDL-Mediated Cellular Cholesterol Efflux in CAS A B * * * Control ACS1 ACS2 CAD Hafiane A. CLC 2013 P10

25 HDL-Mediated Cellular Cholesterol Efflux in CAS *** *** *** Hafiane A. CLC 2013 P10

26 Antioxidant Properties of HDL

27 Antioxidant Properties of HDL LDL LDL-ox PL, FFA LOOX CE-OOX HOPDE HPETE PL-ox POVPC PGPC PAPC O 2- OH Apo AI, J 12-Lipooxygenase a-toc HDL Paraoxonase (PON) Glutathion peroxidase (GPX) PAF-acetyl hydrolase (PAF-AH) Lp-PLA2

28 Generation of truncated phospholipids by oxidative fragmentation and chemical synthesis. Salomon R G Circulation Research. 2012;111: Copyright American Heart Association, Inc. All rights reserved.

29 POVPC activates aortic smooth muscle cell proliferation. Salomon R G Circulation Research. 2012;111: Copyright American Heart Association, Inc. All rights reserved.

30 Prothrombotic activities of oxidatively truncated phospholipids. Salomon R G Circulation Research. 2012;111: Copyright American Heart Association, Inc. All rights reserved.

31 Dehydrative cyclization of isoprostanoid hydroperoxy endoperoxides generates epoxyisoprostanes. Salomon R G Circulation Research. 2012;111: Copyright American Heart Association, Inc. All rights reserved.

32 Antioxidant Properties of HDL No consensus has yet emerged on the proper biomarker of HDL anti-oxidant function.

33 Endothelial cells and HDL HDL exerts beneficial effects on VEC Increase enos stability, mrna and pnos Decrease in NF-kB-mediated inflammatory gene expression Increases endothelial progenitor cells

34 HDL- Vascular endothelial Cell Interaction Campbell S, Genest J, 2012

35 ACS1 HDL ACS2 HDL Medium 200 Hypo a Healthy HDL HDL stimulation of Human Aortic Endothelial enos enos (ps1177: positive phosphorylation) enos (pt495: negative phosphorylation) Loading controls (Ponceau S staining) 37 Choi, H 2013 Unpublished

36 HDL healthy prevents NF-KB nuclear translocation/activation Bessler et al. JCI Confocal microscopy of GFP-anti RelA/p65

37

38 HDL and Endothelial Progenitor Cells Sorrentino SA et al. Circulation 2010;121;

39 Circ Res. 2014;114:

40 Cholesterol efflux ABCA1, ABCG1 and SR-BI Anti-apoptic recruitment of endothelial progenitor cells (EPC) Anti-inflammatory inhibit VCAM-1 expression and adhesion molecules Antioxidative anti-oxldl, inactivate LOOH and oxphospholipase Anti-infectious trypanosome lytic factor and LPS inactivation HDL Vasodilatory NO release, prostacyclin (PGI2) production and enos activation Anti-thrombotic inhibition of platelet aggregation and prostacyclin (PGI2) production Hafiane A. Cholesterol 2013

41 The HDL Proteome Over 200 proteins have been identified as part of the HDL proteome ( eome.html

42

43 Enriched in ACS Enriched in controls clusterin carbonic_anhydrase_i multimerin_2 apolipoprotein_a-iv antithrombin cystatin_c peptidoglycan_recognition_protein_2 alpha-2-glycoprotein_1_zinc-binding inter-alpha_(globulin)_inhibitor_h2 gelsolin angiotensinogen alpha-2-hs-glycoprotein lumican retinol binding protein 4 paraoxonase_3 apolipoprotein_m apolipoprotein_d apolipoprotein_a-ii glycosylphosphatidylinositol_specific_phospholipase_d1 lecithin-cholesterol_acyltransferase apolipoprotein_f vitamin_d_binding_protein heparin_cofactor transferrin paraoxonase_1 apolipoprotein_c-iii transthyretin coagulation_factor_ii_(thrombin) apolipoprotein_c-i apolipoprotein_a-i serum_amyloid_a4_constitutive albumin apolipoprotein_e cathelicidin_antimicrobial_peptide alpha-1-microglobulin/bikunin_precursor apolipoprotein_h C1_protease_inhibitor ceruloplasmin_(ferroxidase) orosomucoid_1 isocitrate_dehydrogenase_3_(nad+)_alph surfactant_protein_b beta-2-microglobulin alpha-1-b_glycoprotein alpha-1_antiproteinase_antitrypsin orosomucoid_2 afamin fibronectin_1 complement_component_1s prenylcysteine_oxidase_1 vitronectin inter-alpha_(globulin)_inhibitor_h4 apolipoprotein_c-ii haptoglobin-related_protein phospholipid_transfer_protein chromosome_1_open_reading_frame_56 integrin_alpha_2b alpha-1_antiproteinase_antitrypsin hemopexin apolipoprotein_c-iv fibrinogen_alpha_chain apolipoprotein_l_1 profilin_1 complement_component_3 complement_factor_b complement_component_4b leucine-rich_alpha-2-glycoprotein_1 alanyl_(membrane)_aminopeptidase serum_amyloid_a_isotype_1_protein

44 HDL Proteome in CVD Riwanto M et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation. 2013;127:

45 Independent confirmation of differentially expressed proteins by Western analysis or ELISA

46 Independent confirmation of differentially enriched proteins by Western analysis or ELISA - Controls

47 Electron paramagnetic resonance spectroscopy (EPR) PLoS One Aug 28;8(8):e doi: /journal.pone

48 The HDL Lipidome Specific lipid species may have a physiological role in HDL function Kontush A et al. J. Lipid Res. 2013;54:

49 Physicochemical properties and lipid class composition of HDL particle subpopulations. Kontush A et al. J. Lipid Res. 2013;54: by American Society for Biochemistry and Molecular Biology

50 Specifically, the content of phosphatidylserine revealed positive correlations with all metrics of HDL functionality, reflecting enrichment of phosphatidylserine in small, dense HDL3.

51 HDL- Vascular endothelial Cell Interaction Campbell S, Genest J, 2012

52 Cellular Cholesterol Efflux Anti-oxidant Anti-inflammatory Vascular Endothelial function Anti-thrombotic The Challenge Develop Biomarkers of HDL Function That can be tested in outcome studies, be reproducible and brought to high throughput.

53 The Short Term Identify Responders, Sub groups HDL Biomarkers presently limited in predicting outcomes IVUS may be the least bad surrogate currently available New imaging modalities ( 18 FDG) and PET/CT scanning High bar of regulatory agencies

54 The Long Term HDL is a Biologically SOUND Target Need to identify new pathways of HDL biogenesis and metabolism Study the structure of HDL in health and in disease (proteomics, lipidomics) Design clinical trials that are highly focused (initially)

55 Points to Take Home HDL particles are complex Genes involved in HDL biogenesis may make better therapeutic targets than genes involved in HDL remodeling (Lipases, CETP) New Gene, new pathways

High density lipoprotein metabolism

High density lipoprotein metabolism High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC

More information

The Target is LDL, HDL not so much

The Target is LDL, HDL not so much The Target is LDL, HDL not so much HDL: A riddle wrapped in a mystery inside an enigma Jacques Genest MD Cardiovascular Research Laboratories McGill University Health Center Disclosure J. Genest MD 2013

More information

Lipid/Lipoprotein Structure and Metabolism (Overview)

Lipid/Lipoprotein Structure and Metabolism (Overview) Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures

More information

Nature Genetics: doi: /ng.3561

Nature Genetics: doi: /ng.3561 Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8

More information

Lipoproteins Metabolism

Lipoproteins Metabolism Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical

More information

Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry

Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Learning Objectives 1. Define lipoproteins and explain the rationale of their formation in blood. 2. List different

More information

Pathophysiology of Lipid Disorders

Pathophysiology of Lipid Disorders Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history

More information

Chapter VIII: Dr. Sameh Sarray Hlaoui

Chapter VIII: Dr. Sameh Sarray Hlaoui Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.

More information

Lipid metabolism in familial hypercholesterolemia

Lipid metabolism in familial hypercholesterolemia Lipid metabolism in familial hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis

More information

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism I. Chylomicrons (exogenous pathway) A. 83% triacylglycerol, 2% protein, 8% cholesterol plus cholesterol esters, 7% phospholipid (esp. phosphatidylcholine)

More information

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:

More information

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing

More information

Glossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein

More information

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,

More information

Cardiology, CardioVascular Center University Hospital Zurich Zurich, Switzerland

Cardiology, CardioVascular Center University Hospital Zurich Zurich, Switzerland Modification of by the lipoxidation product malondialdehyde leads to LOX-1 dependent activation of endothelial PKCbeta-2 and adverse endothelial effects of in patients with coronary artery disease Christian

More information

Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD

Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD Cardiovascular Research Laboratories Research Institute of the McGill University Health Center Disclosure J.

More information

Lipids digestion and absorption, Biochemistry II

Lipids digestion and absorption, Biochemistry II Lipids digestion and absorption, blood plasma lipids, lipoproteins Biochemistry II Lecture 1 2008 (J.S.) Triacylglycerols (as well as free fatty acids and both free and esterified cholesterol) are very

More information

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number

More information

Prof. John Chapman, MD, PhD, DSc

Prof. John Chapman, MD, PhD, DSc Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris

More information

Metabolism and Atherogenic Properties of LDL

Metabolism and Atherogenic Properties of LDL Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal

More information

Acetyl CoA HMG CoA Mevalonate (C6) Dimethylallyl Pyrophosphate isopentenyl Pyrophosphate (C5) Geranyl Pyrophosphate (C10) FarnesylPyrophosphate (C15) Squalene (C30) Lanosterol (C30) 7 Dehydrocholesterol

More information

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global

More information

Lipid Metabolism in Familial Hypercholesterolemia

Lipid Metabolism in Familial Hypercholesterolemia Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis

More information

CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL

CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL You will notice that the endogenous pathway is very similar to the exogenous pathway What is the average daily amount of triacylglycerol

More information

Plasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam

Plasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam Biochemistry Department Plasma lipoproteins & atherosclerosis by Prof.Dr. Maha M. Sallam 1 1. Recognize structures,types and role of lipoproteins in blood (Chylomicrons, VLDL, LDL and HDL). 2. Explain

More information

Summary and concluding remarks

Summary and concluding remarks Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated

More information

ESC Congress 2011 Wednesday August 31st 2011

ESC Congress 2011 Wednesday August 31st 2011 ESC Congress 211 Wednesday August 31st 211 stimulates endothelial CAT-1 expression and L-arginine uptake: a novel mechanism leading to endothelial-protective effects of that is profoundly impaired in patients

More information

The Role of Apolipoprotein CIII in Coronary Artery Disease. Disclosures

The Role of Apolipoprotein CIII in Coronary Artery Disease. Disclosures Miami Cardiac & Vascular Institute Cardiovascular Disease Prevention 15th Annual Symposium February 16, 2017 Nobu Eden Roc Hotel, Miami Beach, Florida. The Role of Apolipoprotein CIII in Coronary Artery

More information

HDL and Its Galaxy of Proteins: What Do they Do? Jay Heinecke, University of Washington

HDL and Its Galaxy of Proteins: What Do they Do? Jay Heinecke, University of Washington HDL and Its Galaxy of Proteins: What Do they Do? Jay Heinecke, University of Washington Disclosures NIH AHA Insilicos Consultant Merck Research Support GSK Research Support Pfizer Research Support Corcept

More information

Central role of apociii

Central role of apociii University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,

More information

HDL : A Treatment Target? ESC Paris M. John Chapman Ph.D., D.Sc., FESC. President, European Atherosclerosis Society

HDL : A Treatment Target? ESC Paris M. John Chapman Ph.D., D.Sc., FESC. President, European Atherosclerosis Society ESC Paris 2011 HDL : A Treatment Target? M. John Chapman Ph.D., D.Sc., FESC Director, Dyslipidemia and Atherosclerosis Research Unit, INSERM, University Pierre and Marie Curie, Hôpital de la Pitié-Salpetriere,

More information

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:

More information

Lipoprotein Particle Profile

Lipoprotein Particle Profile Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular

More information

Cholesterol Metabolism

Cholesterol Metabolism Cholesterol Metabolism Lippincott s Illustrated Review Chapter 18 Steroid Nucleus 1 2 Cholesterol was isolated from gall bladder stones in 1774 3 Sources and Elimination of Cholesterol Synthesis: 1000

More information

Management of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil

Management of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,

More information

Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia

Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia Cholesterol metabolism Function Biosynthesis Transport in the organism Hypercholesterolemia - component of all cell membranes - precursor of bile acids steroid hormones vitamin D Cholesterol Sources: dietary

More information

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Dyslipidemia Endothelial dysfunction Free radicals Immunologic ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and

More information

New Approaches to Lower LDL-C

New Approaches to Lower LDL-C New Approaches to Lower LDL-C CSIM 27 October 2016 Jacques Genest MD Cardiovascular Health Across the Lifespan Program McGill University Health Center Disclosure J. Genest MD 2016 Advisory Board, Speaker

More information

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic

More information

LIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE

LIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE LIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE Sebastiano Calandra Dipartimento di Scienze Biomediche Università di Modena e Reggio Emilia Incidence Rate/1000 200-150 - 100-50 - Women 0 Men

More information

Lipid Lowering in Patients at High Risk for Cardiovascular Disease

Lipid Lowering in Patients at High Risk for Cardiovascular Disease Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel

More information

UC Irvine UC Irvine Previously Published Works

UC Irvine UC Irvine Previously Published Works UC Irvine UC Irvine Previously Published Works Title HDL abnormalities in nephrotic syndrome and chronic kidney disease Permalink https://escholarship.org/uc/item/6h91v4hw Author Vaziri, ND Publication

More information

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Biochemical Analysis (Lipid Panel) Analyte Total Cholesterol Reference Range Patient A < 200 241 LDL-C /= 40 38 Triglycerides

More information

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017 Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital

More information

Reverse Cholesterol Transport and Atherosclerosis

Reverse Cholesterol Transport and Atherosclerosis JCR2014 (2014.12.13@Novotel, Busan, South Korea) Reverse Cholesterol Transport and Atherosclerosis Shizuya Yamashita, MD, PhD, FAHA, FJCC Department of Community Medicine Department ofcardiovascular Medicine

More information

Lipid Metabolism Prof. Dr. rer physiol. Dr.h.c. Ulrike Beisiegel

Lipid Metabolism Prof. Dr. rer physiol. Dr.h.c. Ulrike Beisiegel Lipid Metabolism Department of Biochemistry and Molecular Biology II Medical Center Hamburg-ppendorf 1 Lipids. visceral fat. nutritional lipids 0 1.5 3 4.5 9 h. serum lipids. lipid accumulation in the

More information

Dipartimento di Scienze Cliniche Luigi Sacco SCUOLA DI DOTTORATO DI RICERCA IN SCIENZE BIOCHIMICHE, NUTRIZIONALI E METABOLICHE

Dipartimento di Scienze Cliniche Luigi Sacco SCUOLA DI DOTTORATO DI RICERCA IN SCIENZE BIOCHIMICHE, NUTRIZIONALI E METABOLICHE Dipartimento di Scienze Cliniche Luigi Sacco SCUOLA DI DOTTORATO DI RICERCA IN SCIENZE BIOCHIMICHE, NUTRIZIONALI E METABOLICHE DOTTORATO DI RICERCA IN NUTRIZIONE SPERIMENTALE E CLINICA CICLO XXIII TESI

More information

Lipoprotein Pathophysiology. Lipoprotein Pathophysiology

Lipoprotein Pathophysiology. Lipoprotein Pathophysiology Lipoprotein Pathophysiology Genetic Dyslipidemia Thomas A. Hughes, M.D. Professor of Medicine Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health Science Center GW is a 47

More information

STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty

STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty STRUCTURE OF LIPIDS AND LIPOPROTEINS DEFINTITION: Compounds Insoluble in water But

More information

The Addition of Ezetimibe to Statin therapy in. Patients with Homozygous Familial. Hypercholesterolaemia

The Addition of Ezetimibe to Statin therapy in. Patients with Homozygous Familial. Hypercholesterolaemia The Addition of Ezetimibe to Statin therapy in Patients with Homozygous Familial Hypercholesterolaemia Submitted in fulfilment with the requirements for the degree Master in Medicine (MMed) Dr Adriano

More information

Review Article HDL, Atherosclerosis, and Emerging Therapies

Review Article HDL, Atherosclerosis, and Emerging Therapies Cholesterol, Article ID 891403, 18 pages http://dx.doi.org/10.1155/2013/891403 Review Article HDL, Atherosclerosis, and Emerging Therapies Anouar Hafiane 1 and Jacques Genest 2 1 McGillUniversity,Montreal,QC,CanadaH3A1A1

More information

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien

More information

Niacin Metabolism: Effects on Cholesterol

Niacin Metabolism: Effects on Cholesterol Niacin Metabolism: Effects on Cholesterol By Julianne R. Edwards For Dr. William R. Proulx, PhD, RD Associate Professor of Nutrition and Dietetics In partial fulfillments for the requirements of NUTR342

More information

Tabac et Lipides. Michel FARNIER, MD, PhD, Dijon

Tabac et Lipides. Michel FARNIER, MD, PhD, Dijon Tabac et Lipides Michel FARNIER, MD, PhD, Dijon Dr Farnier reports having received grants, consulting fees and/or honoraria and delivering lectures for Abbott, Akcea/Ionis, Amarin, Amgen, AstraZeneca,

More information

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,

More information

AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5)

AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) Jacques Genest MD Cardiovascular Research Laboratory McGill University Health Center Disclosure J. Genest MD 2012 Advisory Board, Speaker s Bureau, Consultant,

More information

Cholesterol and its transport. Alice Skoumalová

Cholesterol and its transport. Alice Skoumalová Cholesterol and its transport Alice Skoumalová 27 carbons Cholesterol - structure Cholesterol importance A stabilizing component of cell membranes A precursor of bile salts A precursor of steroid hormones

More information

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids: CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation

More information

Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins

Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins Review Article Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins A. R. Tall From the Division of Molecular Medicine, Department

More information

sad EFFECTIVE DATE: POLICY LAST UPDATED:

sad EFFECTIVE DATE: POLICY LAST UPDATED: Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),

More information

5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT

5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT 5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT Prof. Victor Blaton, Ph.D. Department of Clinical Chemistry, Hospital AZ Sint-Jan

More information

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,

More information

Treatment of Atherosclerosis in 2007

Treatment of Atherosclerosis in 2007 Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease

More information

From HDL Structure to Function - How Structural Information Can Help Address Clinical Need March 17, 2012

From HDL Structure to Function - How Structural Information Can Help Address Clinical Need March 17, 2012 From HDL Structure to Function - How Structural Information Can Help Address Clinical Need March 17, 2012 Teaching Objectives There exists no definitive test for risk of cardiovascular disease. Age and

More information

Inflammation: Novel Target for Cardiovascular Risk Reduction

Inflammation: Novel Target for Cardiovascular Risk Reduction Inflammation: Novel Target for Cardiovascular Risk Reduction Andrew Zalewski, M.D. Thomas Jefferson University, Philadelphia GlaxoSmithKline, Philadelphia Why inflammation? Population-based studies: low

More information

Lipidaholics Anonymous Case 2012;13:(1);284 Explaining the unexplainable LDL- P

Lipidaholics Anonymous Case 2012;13:(1);284 Explaining the unexplainable LDL- P 1 Lipidaholics Anonymous Case 2012;13:(1);284 Explaining the unexplainable LDL- P A respected cardiologist contacted me about the following dilemma. He has a primary prevention case which is a woman with

More information

Hypertriglyceridemia, Inflammation, & Pregnancy

Hypertriglyceridemia, Inflammation, & Pregnancy Hypertriglyceridemia, Inflammation, & Pregnancy Richard L. Nemiroff, MD, FACOG, NLA Professor, Clinical Gynecology Perelman School of Medicine University of Pennsylvania Philadelphia, PA Disclosure of

More information

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

More information

Tracking a Killer Molecule

Tracking a Killer Molecule Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive

More information

The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? review Menno Vergeer, 1 Adriaan G. Holleboom, John J. P. Kastelein, and Jan Albert Kuivenhoven Department of Vascular Medicine,

More information

*Address Correspondence to Päivi Pajukanta, MD, PhD, Associate Professor, Department of

*Address Correspondence to Päivi Pajukanta, MD, PhD, Associate Professor, Department of Genetic Causes of High and Low Serum HDL-cholesterol Daphna Weissglas-Volkov 1 and Päivi Pajukanta 1 1 Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California, United

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

Child born in year /3 will die before parents in US (diabetes)

Child born in year /3 will die before parents in US (diabetes) Child born in year 2000-1/3 will die before parents in US (diabetes) ATP III identified 6 components of the metabolic syndrome that relate to CVD 1. Abdominal obesity 2. Atherogenic dyslipidemia (elevated

More information

Regulating Hepatic Cellular Cholesterol

Regulating Hepatic Cellular Cholesterol Under circumstances of cholesterol deficiency, Sterol Regulatory Element Binding Proteins (SREBPs) via binding to DNA nuclear response elements set off genomic production of proteins and enzymes that induce

More information

PPAR history of research

PPAR history of research PPAR Rubens, 1640 PPAR history of research number of publications 3000 2000 1000 0 till now: : 16 296 publications 1985 1990 1995 2000 2005 year liver, brown adipocytes, kidney, heart, skeletal muscles,

More information

Cholesterol; what are the future lipid targets?

Cholesterol; what are the future lipid targets? Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant

More information

A Study of Omega-3 Fatty Acid. Therapy in Patients with. Nephrotic Syndrome

A Study of Omega-3 Fatty Acid. Therapy in Patients with. Nephrotic Syndrome A Study of Omega-3 Fatty Acid Therapy in Patients with Nephrotic Syndrome Dr Samira Siddiqui Renal Unit Glasgow Royal Infirmary Thesis for the degree of MD, Faculty of Medicine, University of Glasgow Submitted

More information

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK

More information

Thematic Review Series: Genetics of Human Lipid Diseases. Genetic causes of high and low serum HDL-cholesterol

Thematic Review Series: Genetics of Human Lipid Diseases. Genetic causes of high and low serum HDL-cholesterol thematic review Thematic Review Series: Genetics of Human Lipid Diseases Genetic causes of high and low serum HDL-cholesterol Daphna Weissglas-Volkov and Päivi Pajukanta 1 Department of Human Genetics,

More information

Best Lipid Treatments

Best Lipid Treatments Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis

More information

The ACCELERATE Trial

The ACCELERATE Trial The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,

More information

Glossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"

More information

Low HDL-levels: leave it or treat it?

Low HDL-levels: leave it or treat it? Cardiology Update 2011 Davos, 14 02 2011 Low HDL-levels: leave it or treat it? Experts: J.P. Kastelein, Amsterdam and U. Landmesser, Zurich Cases: C. Besler, Zurich and I. Sudano, Zurich Mr H.B., 1960

More information

Introduction REVIEW. M. John Chapman*, Wilfried Le Goff, Maryse Guerin, and Anatol Kontush. Keywords

Introduction REVIEW. M. John Chapman*, Wilfried Le Goff, Maryse Guerin, and Anatol Kontush. Keywords European Heart Journal (2010) 31, 149 164 doi:10.1093/eurheartj/ehp399 REVIEW Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin,

More information

Mendelian disorders refer to diseases caused by mutations. Review. Mendelian Disorders of High-Density Lipoprotein Metabolism

Mendelian disorders refer to diseases caused by mutations. Review. Mendelian Disorders of High-Density Lipoprotein Metabolism Review This Review is part of a thematic series on High-Density Lipoprotein, which includes the following articles: Mendelian Disorders of HDL Metabolism Regulation of High-Density Lipoprotein Metabolism

More information

Safety of Anacetrapib in Patients with or

Safety of Anacetrapib in Patients with or Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.

More information

Statins and endothelium function

Statins and endothelium function Statins and endothelium function Matthias Endres Berlin, Germany Klinik und Poliklinik für Neurologie Conflict of interest: research grant from AstraZeneca from prevention to acute therapy... Pleiotropic

More information

Review: The Changing Face of HDL and the Best Way to Measure It

Review: The Changing Face of HDL and the Best Way to Measure It Papers in Press. Published November 22, 2016 as doi:10.1373/clinchem.2016.257725 The latest version is at http://hwmaint.clinchem.aaccjnls.org/cgi/doi/10.1373/clinchem.2016.257725 Clinical Chemistry 63:1

More information

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and

More information

Verhoging van HDL cholesterol: welke opties zijn er binnenkort beschikbaar?

Verhoging van HDL cholesterol: welke opties zijn er binnenkort beschikbaar? HDL en LDL cholesterol state of the art Verhoging van HDL cholesterol: welke opties zijn er binnenkort beschikbaar? Prof. dr. E.S.G. Stroes - internist Academisch Medisch Centrum Amsterdam Increasing HDL

More information

Pipe Cleaners in the Pipeline: Mechanisms of action for novel cardiovascular drugs on the clinical horizon

Pipe Cleaners in the Pipeline: Mechanisms of action for novel cardiovascular drugs on the clinical horizon Cardiovascular Pipeline in Decline Pipe Cleaners in the Pipeline: Mechanisms of action for novel cardiovascular drugs on the clinical horizon Matthew J. Campen, Ph.D., M.S.P.H. UNM Regents Professor of

More information

The relationship between coronary artery disease and low

The relationship between coronary artery disease and low Cellular Phospholipid and Cholesterol Efflux in High-Density Lipoprotein Deficiency Michel Marcil, PhD; Rachel Bissonnette, MSc; Jérôme Vincent, DEA; Larbi Krimbou, DES; Jacques Genest, MD Background Prospective

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

LIPID METABOLISM. Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI

LIPID METABOLISM. Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI LIPID METABOLISM Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI Lipid metabolism is concerned mainly with fatty acids cholesterol Source of fatty acids from dietary fat de novo

More information

Chapter (5) Etiology of Low HDL- Cholesterol

Chapter (5) Etiology of Low HDL- Cholesterol Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the

More information

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown

More information

METABOLISM of ADIPOSE TISSUE

METABOLISM of ADIPOSE TISSUE METABOLISM of ADIPOSE TISSUE 2. LF UK Prof. Rudolf Poledne, PhD. TYPES OF ADIPOSE TISSUE brown adipose tissue subcutaneous adipose tissue visceral adipose tissue ADIPOSE TISSUE FUNCTIONS: thermal isolation

More information

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002 Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low

More information

CHAPTER 1. General Introduction

CHAPTER 1. General Introduction CHAPTER 1 General Introduction General Introduction Contents 1. Lipoproteins and lipid metabolism 1. Exogenous pathway 2. Endogenous pathway 3. Reverse cholesterol pathway 2. Atherosclerosis 1. Pathogenesis

More information